PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.3901 -0.0100 (-2.50%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

July 05, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

June 15, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

June 13, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

June 08, 2022

From PharmaCyte Biotech

Via Business Wire

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

June 02, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 23, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

April 27, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 22, 2022

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 19, 2022

Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...

Via Benzinga

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

April 19, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

April 13, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

April 05, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

March 22, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

March 16, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

February 22, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate ↗

February 14, 2022

PharmaCyte Biotech Inc (NASDAQ: PMCB) updated its activities to lift the FDA's clinical hold on PharmaCyte's treatment for locally advanced, inoperable...

Via Benzinga

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

February 14, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 01, 2022

Gainers Epizyme (NASDAQ:EPZM) shares incr...

Via Benzinga

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

January 06, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

January 04, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

December 28, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

December 15, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

December 08, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

November 30, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

November 12, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗

November 08, 2021

Upgrades For Nektar Therapeutics (NASDAQ:

Via Benzinga

64 Biggest Movers From Yesterday ↗

October 28, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 27, 2021

Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market session. The company's market cap stands at $37.7...

Via Benzinga

60 Biggest Movers From Yesterday ↗

October 27, 2021

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the...

Via Benzinga

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

September 27, 2021

From PharmaCyte Biotech, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.